Summit Therapeutics PLC (NASDAQ:SMMT) Receives $26.15 Average Target Price from Analysts

Posted by Geri Gentry on Aug 6th, 2026

Shares of Summit Therapeutics PLC (NASDAQ:SMMT – Get Free Report) have been assigned an average rating of “Hold” from the sixteen ratings firms that are covering the stock, MarketBeat Ratings reports. Two investment analysts have rated the stock with a sell rating, six have assigned a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $26.1545.

A number of equities research analysts have recently issued reports on SMMT shares. KeyCorp reissued an “overweight” rating on shares of Summit Therapeutics in a research note on Monday, June 1st. Stifel Nicolaus lowered their price objective on shares of Summit Therapeutics from $45.00 to $38.00 and set a “buy” rating for the company in a research report on Friday, July 24th. Guggenheim dropped their target price on shares of Summit Therapeutics from $40.00 to $38.00 and set a “buy” rating for the company in a report on Friday, July 24th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Summit Therapeutics in a report on Friday, July 24th. Finally, Wall Street Zen lowered Summit Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, July 18th.

Get Our Latest Analysis on Summit Therapeutics

Insider Transactions at Summit Therapeutics

In other news, CEO Mahkam Zanganeh acquired 3,810,000 shares of the company’s stock in a transaction dated Friday, June 12th. The stock was acquired at an average cost of $13.12 per share, with a total value of $49,987,200.00. Following the completion of the purchase, the chief executive officer owned 573,883,879 shares of the company’s stock, valued at $7,529,356,492.48. This represents a 0.67% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at this link. Also, CFO Manmeet Singh Soni acquired 50,000 shares of the business’s stock in a transaction that occurred on Thursday, June 4th. The stock was purchased at an average price of $14.45 per share, for a total transaction of $722,500.00. Following the acquisition, the chief financial officer directly owned 3,123,603 shares in the company, valued at approximately $45,136,063.35. This trade represents a 1.63% increase in their position. The SEC filing for this purchase provides additional information. Insiders bought a total of 7,870,000 shares of company stock worth $103,616,900 over the last ninety days. Company insiders own 83.50% of the company’s stock.

Hedge Funds Weigh In On Summit Therapeutics

Institutional investors have recently bought and sold shares of the company. Baker BROS. Advisors LP grew its stake in Summit Therapeutics by 7.9% during the 4th quarter. Baker BROS. Advisors LP now owns 36,391,063 shares of the company’s stock worth $636,480,000 after purchasing an additional 2,668,089 shares in the last quarter. TD Asset Management Inc increased its holdings in Summit Therapeutics by 124.2% during the 4th quarter. TD Asset Management Inc now owns 1,205,272 shares of the company’s stock worth $21,080,000 after purchasing an additional 667,742 shares during the period. Polymer Capital Management HK LTD raised its position in Summit Therapeutics by 73.9% in the 4th quarter. Polymer Capital Management HK LTD now owns 1,421,155 shares of the company’s stock valued at $24,856,000 after purchasing an additional 603,879 shares in the last quarter. Norges Bank acquired a new stake in Summit Therapeutics in the 4th quarter valued at about $24,030,000. Finally, Y Intercept Hong Kong Ltd purchased a new position in shares of Summit Therapeutics in the 1st quarter valued at about $2,269,000. 4.61% of the stock is owned by institutional investors and hedge funds.

Summit Therapeutics Trading Down 1.7%

NASDAQ SMMT opened at $13.53 on Monday. The stock has a fifty day simple moving average of $14.44 and a 200-day simple moving average of $16.40. The stock has a market cap of $10.79 billion, a PE ratio of -12.08 and a beta of -1.23. Summit Therapeutics has a twelve month low of $12.25 and a twelve month high of $30.05.

Summit Therapeutics (NASDAQ:SMMT – Get Free Report) last posted its earnings results on Thursday, July 23rd. The company reported ($0.28) EPS for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.01). Research analysts predict that Summit Therapeutics will post -1.2 EPS for the current year.

Summit Therapeutics Company Profile

(Get Free Report)

Summit Therapeutics plc is a clinical‐stage biotechnology company dedicated to the discovery and development of precision medicines for serious and life‐threatening diseases. The company applies a targeted approach to drug design, focusing on novel mechanisms of action that differentiate its candidates from existing therapies.

Summit’s lead asset, ridinilazole (formerly SMT19969), is being developed to treat Clostridioides difficile infections and has received both Fast Track and Qualified Infectious Disease Product designations from the U.S.